Aldevron News

Webinar Highlights Potential of Researcher-CMO Collaboration in Gene Editing Therapy

As a Project Scientist for the University of California, Los Angeles, Dr. Mark DeWitt has developed a phase 1 GMP-compatible protocol for correcting diseases that cause gene mutations using a CRISPR-Cas9 modular, non-viral gene editing platform. His specific research focuses on a treatment for sickle cell anemia that is more accessible and less costly than a bone marrow transplant—currently, the only way to address the disease. 

Over the past year, DeWitt has partnered with Aldevron and Synthego, industry leaders in CRISPR-Cas9 nucleases and gRNA manufacturing, respectively.

Read More

Aldevron to Divest its Antibody Discovery Unit

Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery businessBrian Walters, current president of the business unit and longtime employee of Aldevronled a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately.  

Read More